Yawei Xu Selected Research

N-methyladenosine

1/2022	FTO-mediated autophagy promotes progression of clear cell renal cell carcinoma via regulating SIK2 mRNA stability.
5/2021	Correction to: Downregulation of lncRNA ZNF582-AS1 due to DNA hypermethylation promotes clear cell renal cell carcinoma growth and metastasis by regulating the N(6)-methyladenosine modification of MT-RNR1.
3/2021	Downregulation of lncRNA ZNF582-AS1 due to DNA hypermethylation promotes clear cell renal cell carcinoma growth and metastasis by regulating the N(6)-methyladenosine modification of MT-RNR1.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yawei Xu Research Topics

Disease

23	Heart Failure 01/2024 - 12/2014
21	Cardiovascular Diseases (Cardiovascular Disease) 04/2023 - 06/2010
15	Atrial Fibrillation 10/2023 - 07/2012
15	Myocardial Infarction 01/2023 - 06/2010
14	Inflammation (Inflammations) 02/2024 - 05/2010
12	Neoplasms (Cancer) 02/2024 - 01/2013
12	Hypertension (High Blood Pressure) 01/2023 - 06/2009
12	Stroke (Strokes) 01/2023 - 04/2015
11	MINOCA 03/2024 - 01/2019
10	Renal Cell Carcinoma (Grawitz Tumor) 11/2023 - 02/2019
10	Hypertrophy 05/2023 - 01/2016
9	Neoplasm Metastasis (Metastasis) 02/2024 - 01/2018
8	Atherosclerosis 01/2023 - 01/2013
8	Coronary Artery Disease (Coronary Atherosclerosis) 01/2023 - 09/2013
7	ST Elevation Myocardial Infarction 12/2022 - 01/2014
6	Cardiac Arrhythmias (Arrythmia) 05/2023 - 02/2012
6	Fibrosis (Cirrhosis) 01/2023 - 01/2016
6	Hemorrhage 01/2022 - 01/2014
6	Left Ventricular Dysfunction 01/2021 - 01/2012
5	Thrombosis (Thrombus) 03/2024 - 06/2010
5	Diabetes Mellitus 01/2023 - 06/2009
5	Hypoxia (Hypoxemia) 10/2022 - 08/2011
4	Hyperplasia 06/2023 - 01/2014
4	Cardiomegaly (Heart Hypertrophy) 01/2023 - 01/2019
4	Right Ventricular Hypertrophy 01/2020 - 08/2011
4	Coronary Disease (Coronary Heart Disease) 12/2017 - 06/2009
4	Type 2 Diabetes Mellitus (MODY) 01/2015 - 01/2013
3	Hyperglycemia 01/2024 - 01/2014
3	Pathologic Constriction (Stenosis) 02/2023 - 06/2010
3	Arteriosclerosis 01/2023 - 01/2021
3	Insulin Resistance 01/2023 - 01/2019
3	Cardiomyopathies (Cardiomyopathy) 01/2023 - 10/2017
3	Heart Diseases (Heart Disease) 01/2023 - 01/2019
3	Carcinogenesis 01/2022 - 02/2018
3	Prostatic Neoplasms (Prostate Cancer) 12/2021 - 01/2020
3	Diabetic Cardiomyopathies 11/2021 - 07/2015
3	Infarction (Infarctions) 01/2021 - 01/2016
3	Varicocele 12/2020 - 06/2019
3	Albuminuria 01/2020 - 01/2014
3	Vascular Remodeling 11/2019 - 01/2017
2	Coronary Stenosis (Coronary Artery Stenosis) 03/2024 - 06/2010
2	von Hippel-Lindau Disease (von Hippel Lindau Disease) 02/2024 - 11/2023
2	Essential Hypertension 02/2024 - 09/2023
2	Tachycardia (Tachyarrhythmias) 10/2023 - 01/2021
2	Hyperhomocysteinemia 01/2023 - 01/2021
2	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2022 - 11/2019
2	Acute Coronary Syndrome 01/2022 - 01/2022

Drug/Important Bio-Agent (IBA)

20	omega-Chloroacetophenone (Mace)IBA 03/2024 - 06/2010
13	Biomarkers (Surrogate Marker)IBA 11/2023 - 01/2014
10	Proteins (Proteins, Gene)FDA Link 01/2023 - 01/2016
6	LipidsIBA 01/2023 - 06/2009
6	oxidized low density lipoproteinIBA 05/2019 - 06/2009
5	Long Noncoding RNAIBA 06/2023 - 01/2018
5	Glucose (Dextrose)FDA LinkGeneric 01/2023 - 02/2012
5	LDL CholesterolIBA 01/2023 - 06/2009
5	CreatinineIBA 01/2021 - 10/2013
5	AlbuminsIBA 01/2021 - 10/2013
4	Indicators and Reagents (Reagents)IBA 03/2024 - 01/2021
4	Antihypertensive Agents (Antihypertensives)IBA 09/2023 - 01/2015
4	DNA (Deoxyribonucleic Acid)IBA 06/2023 - 03/2021
4	HDL LipoproteinsIBA 01/2023 - 02/2012
4	CholesterolIBA 01/2023 - 06/2009
4	HDL CholesterolIBA 01/2023 - 02/2012
4	MicroRNAs (MicroRNA)IBA 10/2021 - 02/2018
3	RNA (Ribonucleic Acid)IBA 02/2024 - 01/2021
3	Amlodipine (Norvasc)FDA LinkGeneric 02/2024 - 01/2019
3	Messenger RNA (mRNA)IBA 11/2023 - 12/2018
3	CytokinesIBA 05/2023 - 10/2013
3	Triglycerides (Triacylglycerol)IBA 01/2023 - 01/2019
3	Myosin Light Chains (Myosin Essential Light Chain)IBA 01/2023 - 10/2017
3	C-Reactive ProteinIBA 10/2022 - 01/2012
3	Caspase 3 (Caspase-3)IBA 10/2022 - 01/2016
3	N-methyladenosineIBA 01/2022 - 03/2021
3	Superoxide DismutaseIBA 11/2021 - 08/2011
3	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 12/2020 - 06/2009
3	AnticoagulantsIBA 01/2020 - 01/2020
2	TabletsIBA 02/2024 - 09/2023
2	Olmesartan Medoxomil (Votum)FDA Link 02/2024 - 09/2023
2	CollagenIBA 06/2023 - 01/2018
2	S- (2- chloro- 1,1,2- trifluoroethyl)cysteine (CTFC)IBA 01/2023 - 01/2021
2	HMGB1 Protein (HMG1)IBA 10/2022 - 09/2013
2	Complement System Proteins (Complement)IBA 01/2022 - 11/2019
2	Neutralizing AntibodiesIBA 01/2022 - 12/2018
2	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2022 - 12/2020
2	AdipokinesIBA 01/2022 - 01/2018
2	Small Interfering RNA (siRNA)IBA 12/2021 - 01/2019
2	Streptozocin (Streptozotocin)FDA Link 11/2021 - 01/2013
2	Reactive Oxygen Species (Oxygen Radicals)IBA 11/2021 - 01/2016
2	InflammasomesIBA 11/2021 - 01/2020
2	Malondialdehyde (Propanedial)IBA 11/2021 - 01/2016
2	Glutathione PeroxidaseIBA 11/2021 - 01/2016
2	Triiodothyronine (Liothyronine)FDA LinkGeneric 01/2021 - 01/2012

Therapy/Procedure

10	Therapeutics 01/2023 - 01/2016
7	Patient Readmission 11/2023 - 01/2017
6	Percutaneous Coronary Intervention 01/2022 - 06/2010
5	Catheter Ablation 05/2023 - 05/2013
5	Cryosurgery 01/2022 - 11/2019
5	Stents 01/2021 - 06/2010
4	Ligation 10/2022 - 12/2017
3	Secondary Prevention 12/2020 - 01/2019